Silence Therapeutics (SLN) Asset Utilization Ratio (2025 - 2026)
Silence Therapeutics (SLN) posted Asset Utilization Ratio of 0.01 for Q1 2026, up 69.37% sequentially from 0.0 in Q4 2025, and down 95.24% YoY from 0.14 in Q1 2025.
Silence Therapeutics (SLN) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Silence Therapeutics has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.01 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 95.24% year-over-year to 0.01 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01 (down 95.24% YoY) and the FY2025 annual result came in at 0.0, down 98.75% from the prior year.
- Asset Utilization Ratio advanced to 0.01 in Q1 2026 per SLN's latest filing, from 0.0 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.17 in Q3 2025 and troughed at 0.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.01 |
| Mar 31, 2026 | 0.01 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.17 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.14 |